Skip to content
value.today

EDAP TMS

EDA.F
$200 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$71 M
For year ending December-2025
Net income
$-29 M
-41.5% margin
SEC filing
Employees
—

EDAP TMS in brief

EDAP TMS is a listed company in the Medical Equipment industry, based in France. Its last known market value was $200 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $71 M and a net loss of $29 M. Its largest product and service lines by sales in 2025 were Goods (69%), Spare parts and services (16%) and RPPs & leases (15%). By market, the largest shares of its 2025 sales came from USA (40%), Asia (28%) and France (7%). Its shares trade under the symbol EDA.F (Frankfurt).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

EDAP TMS timeline

1 events, 1997
  1. 1997
  2. 🔔
    · approximate
    Initial public offering on Frankfurt

Events of EDAP TMS from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$103 M$205 M$308 M$410 M20202021202220232024

World rank over time

▼ down 892 places since 2020
2020-01-01: #16996#16,99620202021-01-01: #15793#15,79320212022-01-07: #18836#18,83620222022-12-25: #14225#14,22520222023-07-30: #14991#14,99120232024-01-05: #17888#17,8882024

Rank in France: #290 (Jan 2020) · #285 (Jan 2021) · #276 (Jan 2022) · #206 (Dec 2022) · #216 (Jul 2023) · #244 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-47.0%
Operating margin
-35.0%
Return on equity
-193.1%
Liabilities / assets
75.4%
Net debt
$-2M
Revenue growth
+1.6%
R&D / revenue
13.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2017: revenue $40M, net income $-1M$40MFY17Fiscal year ending Dec 2018: revenue $46M, net income $-0M$46MFY18Fiscal year ending Dec 2019: revenue $50M, net income $2M$50MFY19Fiscal year ending Dec 2020: revenue $48M, net income $-2M$48MFY20Fiscal year ending Dec 2021: revenue $52M, net income $1M$52MFY21Fiscal year ending Dec 2022: revenue $58M, net income $-3M$58MFY22Fiscal year ending Dec 2024: revenue $69M, net income $-21M$69MFY24Fiscal year ending Dec 2025: revenue $71M, net income $-29M$71MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$71M+1.6%$-25M$-29M-41.5%
Dec 2024$69M+19.9%$-22M$-21M-29.7%
Dec 2022$58M+11.2%$-4M$-3M-5.3%
Dec 2021$52M+9.6%$-2M$1M1.6%
Dec 2020$48M-5.5%$0M$-2M-4.1%
Dec 2019$50M+8.7%$2M$2M3.4%
Dec 2018$46M+14.7%$-2M$-0M-0.9%
Dec 2017$40M—$-2M$-1M-1.9%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-16M——$-0.78—
Dec 2024$-15M——$-0.55—
Dec 2022$-3M——$-0.09—
Dec 2021$5M——$0.02—
Dec 2020$2M——$-0.07—
Dec 2019$4M——$0.06—
Dec 2018$0M$1M$-1M$-0.01—
Dec 2017$-3M$1M$-5M$-0.02—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$80M
Net income, trailing 12 months
$-37M
RevenueNet income
Three months to Mar 2025: revenue $14M, net income $-7M$14MMar ’25Three months to Jun 2025: revenue $10M, net income $-6M$10MJun ’25Three months to Sep 2025: revenue $8M, net income $-6M$8MSep ’25Three months to Dec 2025 (from the annual report): revenue $39M, net income $-9M$39MDec ’25Three months to Mar 2026: revenue $18M, net income $-9M$18MMar ’26Three months to Jun 2026: revenue $13M, net income $-14M$13MJun ’26Three months to Sep 2026: revenue $10M, net income $-4M$10MSep ’26

Latest quarter to Sep 2026: revenue $10M (+25.5% on a year earlier), net income $-4M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of EDAP TMS with the US Securities and Exchange Commission.

Annual results

Revenue
$71 M
Operating income
$-25 M
Net income
$-29 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$79 M
Total liabilities
$60 M
Total equity
$19 M

As of December-2025

Insider trading at EDAP TMS#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
451 K
9 purchases, 8 insiders
Sold, 12 months
0
0 sales, 0 insiders
Net, 12 months
451 K
open market only
Insiders on file
8
since
$409 K$0May 2026: bought $42 K (1 trades), sold $0 (0 trades)May 26Aug 2026: bought $409 K (8 trades), sold $0 (0 trades)Aug
Bought (open market)Sold (open market)Hover a month for the totals
EDAP TMS: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David R. HornDirectorBuy+10,0004.750—local10,000Form 4
filed Fran SchulzDirectorBuy+10,0004.750—local15,100Form 4
filed Sanket ShahGeneral Counsel & Corp SecBuy+5,0004.750—local72,500Form 4
filed Steven AnnenSVP, Marketing & Product Mgmt.Buy+5,0004.75024 Klocal136,490Form 4
filed Kenneth S. MobeckChief Financial OfficerBuy+5,0004.750—local181,610Form 4
filed Ryan RhodesChief Executive Officer, DirectorBuy+21,0004.750100 Klocal626,649Form 4
filed Joshua LevineDirectorBuy+10,0004.75048 Klocal45,000Form 4
filed Lance WillseyDirectorBuy+50,0004.750238 Klocal1.29 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars

Markets and events: EDAP TMS#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
365,242
1.0% of shares · 9.37 days to cover
Shares sold short, last 10 reportsAll stocks →

Fails to deliver

  • : 234 shares at $4.23
  • : 690 shares at $4.07
  • : 529 shares at $4.22
  • : 14 shares at $4.41
  • : 946 shares at $4.18

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

EDAP TMS scorecard#

Passes 6 of the 11 checks that could be worked out: strongest in financial health (3 of 3), weakest in profitability (1 of 4). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth1 of 3
    • ✓Revenue grew in the newest year1.6%Revenue up 1.6% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.78 vs -0.55Diluted EPS -0.78 in fiscal 2025 against -0.55 the year before (report's currency).
    • ✗Net income higher than five years earlier-$29 M-$29 M in fiscal 2025 against -$2 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$29 MNet income -$29 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✓Operating margin above its peers' median-35.0%-35.0% against Medical Equipment's median of -38.5% (8 companies).
    • ✗Return on equity above 15%-94.5%-94.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-35.0%-35.0% in fiscal 2025 against -7.7% in 2022.
  • Financial health3 of 3
    • ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.54 at the end of fiscal 2025.
    • ✓Debt below equity0.9×Debt to equity 0.93 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $2 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year0.4%Diluted shares up 0.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Medical Equipment, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from EDAP TMS's statements, beside the median of Medical Equipment.

EDAP TMS: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-35.0%-38.5%
Net margin-41.5%-44.9%
Return on equity-94.5%-94.5%
Revenue growth1.6%15.6%
Debt to equity0.93×—

3of 9on the Piotroski tests of financial strength

  • Net loss of $29 million.
  • More cash than debt: net cash of $2 million.

EDAP TMS: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in millions of each column's currency; per-share figures in the column's currency; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

EDAP TMS: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025 · USDFY 2024to Dec 31, 2024 · USDFY 2023to Dec 31, 2023 · EURFY 2022to Dec 31, 2022 · EURFY 2021to Dec 31, 2021 · EURFY 2020to Dec 31, 2020 · EURFY 2019to Dec 31, 2019 · EURFY 2018to Dec 31, 2018 · EURFY 2017to Dec 31, 2017 · EURFY 2016to Dec 31, 2016 · EUR
Income statement
Revenue71696055444245393636
Cost of revenue41413631262324222119
Gross profit30292424181821171516
Research and development9.78.47.04.93.44.53.74.13.93.9
Selling and marketing27272316119.311119.58.9
General and administrative1815157.25.94.34.23.63.43.3
Operating expenses5551442820———1716
Operating income−25−22−20−4.3−1.60.32.2−1.3−2.00.4
Interest and finance income0.30.91.30.4——————
Interest expense and finance costs0.80.30.20.20.10.10.20.10.00.1
Net interest income——1.10.20.1−0.1−0.10.82.63.9
Income before tax−29−20−21−2.10.9−1.22.20.0−0.34.4
Income tax0.40.30.60.80.20.50.70.40.40.6
Net income including minority interests−29−21————————
Net income attributable to shareholders−29−21−21−2.90.7−1.7r1.5r−0.3r−0.7r3.8
Earnings per share, basic-0.78-0.55-0.57-0.090.02-0.060.05-0.01-0.020.14
Earnings per share, diluted-0.78-0.55-0.57-0.090.02-0.060.05-0.01-0.020.13
Shares, weighted average (basic)37373734322929292928
Shares, weighted average (diluted)37373734322930292929
Balance sheet
Cash and cash equivalents20314363472521192022
Short-term investments0—0000——0—
Receivables15r19181311111112119.1
Inventory7.8r1915127.58.08.27.26.78.0
Other current assets1.2r1.30.70.70.60.40.40.40.50.5
Current assets57737891674542404041r
Property, plant and equipment9.97.65.93.7r3.63.74.1r3.0r3.72.8
Right-of-use (leased) assets2.0r2.71.71.81.61.92.6———
Goodwill0.8r2.52.42.42.42.42.42.42.42.4
Other intangible assets1.8r1.11.10.70.70.80.80.80.50.1
Total assets798992101775553494747
Accounts payable1213116.65.55.76.06.36.25.6
Debt due within a year2.1r2.51.61.60.84.50.50.50.40.2
Current liabilities37392822182217171615
Long-term debt162.22.03.64.91.11.01.30.80.4
Lease liabilities (non-current)1.1r1.70.90.90.91.11.7———
Total liabilities60473529272926242222
Retained earnings−129−99−64−42−39−40−38−40−40−39
Shareholders' equity19425772502627252524
Total liabilities and equity798992101775553494747
Shares outstanding37373737332929292929
Cash-flow statement
Depreciation and amortization3.42.81.91.61.92.11.91.61.61.0
Cash from operating activities−16−15−15−3.04.42.03.80.2−3.11.2r
Capital expenditure———————−0.8−1.0−0.9r
Intangible assets bought−0.8−0.2−0.5−0.1−0.1−0.1−0.0−0.4−0.5−0.2
Cash from investing activities−5.7−4.5−4.3−2.4−1.6−2.0−1.5−1.6−2.0−0.4
Debt issued122.8—0.31.14.80.71.01.63.2
Debt repaid−2.7−1.7−1.6−0.8−1.4−0.5−1.1−0.4−0.2−0.3r
Shares issued———2221———0.56.2
Cash from financing activities8.65.0−0.922203.2−0.71.22.97.6r
Exchange-rate effect on cash3.0−2.9——−0.60.6−0.2−0.30.2−0.0
Change in cash−11−17−2016223.81.4−0.5−2.08.4
Report10-K10-K20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What EDAP TMS sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Goods$49 M69%
  • Spare parts and services$11 M16%
  • RPPs & leases$10 M15%

Business segments

  • High Intensity Focused Ultrasound (HIFU)$37 M53%
  • DISTRIB Division$26 M36%
  • Lithotripsy (ESWL)$7 M11%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where EDAP TMS operates: 6 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 6 subsidiaries on file.

EDAP TMS: countries of operation
CountryPresenceRevenue there
🇫🇷 FranceHeadquarters1 subsidiary$5 M6.5%
🇩🇪 Germany1 subsidiary—
🇯🇵 Japan1 subsidiary—
🇲🇾 Malaysia1 subsidiary—
🇨🇭 Switzerland1 subsidiary—
🇺🇸 USA1 subsidiary$29 M40%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at EDAP TMS#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.7 M
Mr. Rhodes
Other top executives, average
$860 K
the CEO earned 2× this
$100 invested is now
$62
EDAP TMS: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Rhodes$1.7 M$2.7 M$860 K$62
2024Chief executive$1.3 M$769 K$738 K$42

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at EDAP TMS#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Material agreement 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 6

EDAP TMS: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
New debtUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

How EDAP TMS compares in Medical Equipment

  • Revenue$71 M · higher than 33% of 19
  • Net margin-47.0% · higher than 19% of 17
  • Revenue growth1.6% · higher than 25% of 13

Peer comparison · Medical Equipment

CompanyMarket capP/ENet marginRev. growth
EDAP TMS🇫🇷$200 M—-47.0%+1.6%
Avita Medical, Inc.🇺🇸$525 M—-42.6%+11.5%
Viemed Healthcare, Inc.🇺🇸$367 M23.5×5.0%+20.5%
Electromed, Inc.🇺🇸$341 M28.6×15.8%+15.3%
Profound Medical Corp.🇨🇦$240 M—-137.4%+50.8%
Streamex Corp.🇺🇸$52 M——+100.0%
TELA Bio, Inc.🇺🇸$52 M—-53.6%+15.8%
IRIDEX Corporation🇺🇸$12 M—-6.9%+8.2%
Beyond Air, Inc.🇺🇸$4 M—-407.6%+107.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at EDAP TMS? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show EDAP TMS's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about EDAP TMS? Suggest a correction